Toward Improved Diagnosis Accuracy and Treatment of Children, Adolescents, and Young Adults With Ependymoma: The International SIOP Ependymoma II Protocol.
Pierre Leblond, Maura Massimino, Martin English...
https://pubmed.ncbi.nlm.nih.gov/35720069/Actively Recruiting
Led by Centre Leon Berard · Updated on 2024-04-26
536
Participants Needed
40
Research Sites
165 weeks
Total Duration
Researchers are conducting an international clinical program to improve diagnosis, treatment, and understanding of childhood ependymoma in patients under 22 years old. The study aims to harmonize staging and care standards, assess biological markers, and develop treatment recommendations based on age, tumor location, and surgical outcomes. Patients are categorized into three groups based on residual disease and eligibility for radiotherapy to test different therapeutic strategies. The study includes three treatment strata Stratum 1 evaluates the impact of a 16-week chemotherapy regimen with VEC-CDDP after surgery and conformal radiotherapy in patients aged over 12 months to under 22 years with completely removed tumors. Stratum 2 examines the addition of high-dose methotrexate to VEC chemotherapy in patients with residual disease, followed by conformal radiotherapy and possibly an 8 Gy radiotherapy boost for inoperable residual tumors. Stratum 3 studies dose-dense chemotherapy with or without valproate in children under 12 months or those ineligible for radiotherapy. Patients not meeting these criteria enter an observational registry. Participants undergo centralized pathology and imaging reviews to confirm diagnosis and tumor resection status. Assessments include MRI scans, biological marker evaluations, and response to treatments. Researchers monitor progression-free survival, gross total resection rates, treatment response, neuropsychological and neuroendocrine effects, and safety over several years. The study involves scheduled visits, laboratory tests, and follow-up for up to five years to evaluate long-term outcomes.
CONDITIONS
An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma
P
Pierre LEBLOND, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Centre Leon Berard
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 month
Participants undergo surgery for tumor removal followed by a central review of imaging and pathology to assess the completeness of resection and confirm diagnosis.
1 to 2 visits depending on surgery and review timing
Duration - Varies by stratum: up to 16 weeks of chemotherapy plus radiotherapy schedules
Participants receive treatment based on their assigned stratum including chemotherapy, conformal radiotherapy, and possible second look surgery depending on residual disease and eligibility.
Multiple visits during chemotherapy and radiotherapy treatment phases
Duration - Up to 5 years after the end of treatment
Participants are monitored after treatment completion for disease progression, survival, and long-term effects including neuropsychological and neuroendocrine assessments.
Regular follow-up visits over several years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
6
Have more questions? Get in touch with our team for quick support
Pierre Leblond, Maura Massimino, Martin English...
https://pubmed.ncbi.nlm.nih.gov/35720069/Centre Leon Berard
Lead Sponsor